Squarepoint’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Squarepoint’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17,550	Closed	-$1.88M	–	4179
2023 Q1	$1.88M	Sell	17,550 -16,157	-48%	-$1.86M	0.01%	1450
2022 Q4	$3.71M	Buy	33,707 +13,647	+68%	+$885K	0.01%	983
2022 Q3	$1.18M	Sell	20,060 -12,628	-39%	-$578K	0.01%	1649
2022 Q2	$923K	Buy	+32,688	New	+$947K	0.01%	1658

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Squarepoint's RXDX Position: Q2 2023 in Review

Squarepoint sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 17,550 shares — an estimated $1.88M sold.

Squarepoint first reported a position in RXDX in Q2 2022 and held it in 4 quarters. The position peaked at $3.71M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Squarepoint reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Squarepoint sold 17,550 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.88M.
Squarepoint first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
Squarepoint's Prometheus Biosciences, Inc. Common Stock position peaked at $3.71M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Squarepoint's 13F filing for Q2 2023, filed 14 Aug 2023.